Fungal infection

Current Anaesthesia and Critical Care

Volumn 16, Issue 4, 2005, Pages 231-241

  Soni, Neil ^a   Wagstaff, Adrian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Azoles; Candida infection; Echinocandins; Fungal infection; Intensive care unit; Polyenes

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; STEROID; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLOOD CULTURE; BLURRED VISION; BONE MARROW SUPPRESSION; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CLINICAL FEATURE; COLOR VISION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; ENDOCARDITIS; ENDOPHTHALMITIS; FATIGUE; FLUSHING; FUNGAL COLONIZATION; FUNGEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INFECTION RISK; LIVER DYSFUNCTION; LIVER TOXICITY; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PHOTOPHOBIA; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; VISUAL DISORDER;

EID: 33644661575     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2005.11.010     Document Type: Article

References (65)

1. D. Pittet M. Monod I. Filthuth E. Frenk P.M. Suter R. Auckenthaler Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections Am J Med 91 3B 1991 256S-263S
2. P.R. Neumann S.R. Rakower The risk of positive cultures for Candida in the critically ill patient Crit Care Med 6 2 1978 73-76
3. D. Pittet M. Monod P.M. Suter E. Frenk R. Auckenthaler Candida colonization and subsequent infections in critically ill surgical patients Ann Surg 220 6 1994 751-758
4. G. Alangaden P.H. Chandrasekar E. Bailey Y. Khaliq Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team Bone Marrow Transplant 14 6 1994 919-924
5. G.P. Bodey G. Samonis K. Rolston Prophylaxis of candidiasis in cancer patients Semin Oncol 17 3 Suppl 6 1990 24-28
6. P.H. Chandrasekar C.M. Gatny The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team J Antimicrob Chemother 33 2 1994 309-318
7. C. Lumbreras V. Cuervas-Mons P. Jara A. del Palacio V.S. Turrion C. Barrios et. al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation J Infect Dis 174 3 1996 583-588
8. J.H. van Burik W. Leisenring D. Myerson R.C. Hackman H.M. Shulman G.E. Sale et. al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients Medicine (Baltimore) 77 4 1998 246-254
9. D.J. Winston A. Pakrasi R.W. Busuttil Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial Ann Intern Med 131 10 1999 729-737
10. D.B. Safran E. Dawson The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit Arch Surg 132 11 1997 1184-1188 [discussion 1188-9]
11. P. Eggimann P. Francioli J. Bille R. Schneider M.M. Wu G. Chapuis et. al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients Crit Care Med 27 6 1999 1066-1072
12. P. Eggimann J. Garbino D. Pittet Management of Candida species infections in critically ill patients Lancet Infect Dis 3 12 2003 772-785
13. M.H. Desai D.N. Herndon Eradication of Candida burn wound septicemia in massively burned patients J Trauma 28 2 1988 140-145
14. R.L. Sheridan J.M. Weber L.G. Budkevich R.G. Tompkins Candidemia in the pediatric patient with burns J Burn Care Rehabil 16 4 1995 440-443
15. J.R. Maenza J.C. Keruly R.D. Moore R.E. Chaisson W.G. Merz J.E. Gallant Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients J Infect Dis 173 1 1996 219-225
16. J.D. Cartledge J. Midgley B.G. Gazzard Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis AIDS 11 15 1997 1839-1844
17. D.M. Kuhn M.A. Ghannoum Candida biofilms: Antifungal resistance and emerging therapeutic options Curr Opin Invest Drugs 5 2 2004 186-197
18. M.A. Pfaller R.N. Jones G.V. Doern H.S. Sader R.J. Hollis S.A. Messer International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group J Clin Microbiol 36 7 1998 1886-1889
19. D.I. Soutter T.R. Todd Systemic candidiasis in a surgical intensive care unit Can J Surg 29 3 1986 197-199
20. R.T. Mehta S. Poddar M. Kalidas R. Gomez-Flores K. Dulski Role of macrophages in the candidacidal activity of liposomal amphotericin B J Infect Dis 175 1 1997 214-217
21. J. Adler-Moore R. Proffitt Development characterization efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B J Liposomal Res 3 3 1993 429-450
22. E.J. Anaissie G.N. Mattiuzzi C.B. Miller G.A. Noskin M.J. Gurwith R.D. Mamelok et. al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion Antimicrob Agents Chemother 42 3 1998 606-611
23. B. Beovic T. Lejko-Zupanc J. Pretnar Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion Eur J Clin Microbiol Infect Dis 16 7 1997 507-511
24. R.N. Brogden K.L. Goa A.J. Coukell Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis Drugs 56 3 1998 365-383
25. G.A. Noskin L. Pietrelli G. Coffey M. Gurwith L.J. Liang Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients Clin Infect Dis 26 2 1998 461-467
26. T.J. Walsh N.L. Seibel C. Arndt R.E. Harris M.J. Dinubile A. Reboli et. al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections Pediatr Infect Dis J 18 8 1999 702-708
27. D. Debruyne Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses Clin Pharmacokinet 33 1 1997 52-77
28. R. Aust F.E. Kruse A. Wildfeuer G. Pfaff K. Rohrschneider H.E. Volcker Fluconazole level in aqueous humor after oral drug administration in humans Ophthalmologe 92 6 1995 829-832 [in German]
29. M.J. Humphrey S. Jevons M.H. Tarbit Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans Antimicrob Agents Chemother 28 5 1985 648-653
30. K. Quabeck K.D. Muller D.W. Beelen H. Dermoumi M. Kolbel J. Kraft et. al. Prophylaxis and treatment of fungal infections with fluconazole in bone marrow transplant patients Mycoses 35 9-10 1992 221-224
31. K.H. Duswald L. Pittrow A. Penk Value of high dosage fluconazole in therapy of Candida infections in intensive care medicine Anaesthesiol Reanim 23 5 1998 134-138 [in German]
32. L. Ostrosky-Zeichner A.M. Oude Lashof B.J. Kullberg J.H. Rex Voriconazole salvage treatment of invasive candidiasis Eur J Clin Microbiol Infect Dis 22 11 2003 651-655
33. T.J. Walsh M.O. Karlsson T. Driscoll A.G. Arguedas P. Adamson X. Saez-Llorens et. al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration Antimicrob Agents Chemother 48 6 2004 2166-2172
34. T.J. Walsh P. Pappas D.J. Winston H.M. Lazarus F. Petersen J. Raffalli et. al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 4 2002 225-234
35. G.M. Keating Posaconazole Drugs 65 11 2005 1553-1567 [discussion 1568-9]
36. M. Cuenca-Estrella A. Gomez-Lopez E. Mellado G. Garcia-Effron J.L. Rodriguez-Tudela In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates Antimicrob Agents Chemother 48 8 2004 3107-3111
37. M.A. Pfaller S.A. Messer L. Boyken C. Rice S. Tendolkar R.J. Hollis et. al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp J Clin Microbiol 42 7 2004 3137-3141
38. K. De Beule J. Van Gestel Pharmacology of itraconazole Drugs 61 Suppl 1 2001 27-37
39. M.D. Sharpe C. Ghent D. Grant G.L. Horbay J. McDougal W. David Colby Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study Transplantation 76 6 2003 977-983
40. D.J. Winston R.T. Maziarz P.H. Chandrasekar H.M. Lazarus M. Goldman J.L. Blumer et. al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med 138 9 2003 705-713
41. A. Catanzaro Coccidiomycosis Semin Respir Crit Care Med 25 2 2004 123-128
42. R.A. Assaly J.R. Hammersley D.E. Olson A. Farrouk A. Zaher G.V. Amurao et. al. Disseminated blastomycosis J Am Acad Dermatol 48 1 2003 123-127
43. D.W. Denning Echinocandin antifungal drugs Lancet 362 9390 2003 1142-1151
44. H.W. Boucher A.H. Groll C.C. Chiou T.J. Walsh Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy Drugs 64 18 2004 1997-2020
45. A. Espinel-Ingroff In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature Rev Iberoam Micol 20 4 2003 121-136
46. V.A. Morrison The role of caspofungin and the echinocandins in the antifungal armamentarium Curr Opin Invest Drugs 3 10 2002 1432-1436
47. J. Mora-Duarte R. Betts C. Rotstein A.L. Colombo L. Thompson-Moya J. Smietana et. al. Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 25 2002 2020-2029
48. A.H. Groll T. Stergiopoulou E. Roilides T.J. Walsh Micafungin: pharmacology, experimental therapeutics and clinical applications Expert Opin Invest Drugs 14 4 2005 489-509
49. N.T. de Wet A.J. Bester J.J. Viljoen F. Filho J.M. Suleiman E. Ticona et. al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis Aliment Pharmacol Ther 21 7 2005 899-907
50. J.A. van Burik V. Ratanatharathorn D.E. Stepan C.B. Miller J.H. Lipton D.H. Vesole et. al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 10 2004 1407-1416
51. A.K. Zaas W.J. Steinbach Micafungin: The US perspective Expert Rev Anti Infect Ther 3 2 2005 183-190
52. Y. Higashiyama S. Kohno Micafungin: A therapeutic review Expert Rev Anti Infect Ther 2 3 2004 345-355
53. S. Kohno T. Masaoka H. Yamaguchi T. Mori A. Urabe A. Ito et. al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan Scand J Infect Dis 36 5 2004 372-379
54. S.V. Komshian A.K. Uwaydah J.D. Sobel L.R. Crane Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome Rev Infect Dis 11 3 1989 379-390
55. A. Sitges-Serra M. Girvent Catheter-related bloodstream infections World J Surg 23 6 1999 589-595
56. J.H. Rex Editorial response: Catheters and candidemia Clin Infect Dis 22 3 1996 467-470
57. E. Rubinstein E.R. Noriega M.S. Simberkoff R. Holzman J.J. Rahal Jr Fungal endocarditis: Analysis of 24 cases and review of the literature Medicine (Baltimore) 54 4 1975 331-334
58. C.J. Wells G.J. Leech A.M. Lever M.H. Wansbrough-Jones Treatment of native valve Candida endocarditis with fluconazole J Infect 31 3 1995 233-235
59. H. Schmidt A.R. Fischedick P.E. Peters H.J. von Lengerke Candida abscesses in the liver and spleen. The sonographic and computed tomographic morphology Dtsch Med Wochenschr 111 21 1986 816-820 [in German]
60. G.P. Howell S.D. Holt I.B. Tiwari Candida septicaemia and abscess formation following multiple injuries with blunt rupture of the stomach J R Army Med Corps 134 2 1988 74-75
61. J.S. Solomkin A.M. Flohr R.L. Simmons Indications for therapy for fungemia in postoperative patients Arch Surg 117 10 1982 1272-1275
62. M.H. Nguyen V.L. Yu Meningitis caused by Candida species: An emerging problem in neurosurgical patients Clin Infect Dis 21 2 1995 323-327
63. G. Foulds D.R. Brennan C. Wajszczuk A. Catanzaro D.C. Garg W. Knopf et. al. Fluconazole penetration into cerebrospinal fluid in humans J Clin Pharmacol 28 4 1988 363-366
64. P.J. McDonnell J.M. McDonnell R.H. Brown W.R. Green Ocular involvement in patients with fungal infections Ophthalmology 92 5 1985 706-709
65. F.E. Thomas Jr C.E. Martin R.D. Fisher R.H. Alford Candida albicans infection of sternum and costal cartilages: Combined operative treatment and drug therapy and 5-fluorocytosine Ann Thorac Surg 23 2 1977 163-166